STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight (MPLT) CEO Kroeger sells 49,744 shares under Rule 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported open‑market sales of Voting Common Stock. Over May 4–6, 2026, he sold a total of 49,744 shares in multiple transactions classified as open‑market sales under code S, at prices reported as weighted averages.

The filing shows these transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted on December 29, 2025, meaning they were pre‑scheduled. After the reported sales, Kroeger directly holds 1,580,820 shares of Voting Common Stock and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse have voting and dispositive power.

Positive

  • None.

Negative

  • None.
Insider Kroeger Christopher A.
Role Chief Executive Officer
Sold 49,744 shs ($1.41M)
Type Security Shares Price Value
Sale Voting Common Stock 8,098 $28.04 $227K
Sale Voting Common Stock 15,603 $29.13 $455K
Sale Voting Common Stock 9,544 $28.12 $268K
Sale Voting Common Stock 928 $29.00 $27K
Sale Voting Common Stock 9,136 $27.50 $251K
Sale Voting Common Stock 5,427 $28.37 $154K
Sale Voting Common Stock 311 $29.56 $9K
Sale Voting Common Stock 697 $30.08 $21K
holding Voting Common Stock -- -- --
Holdings After Transaction: Voting Common Stock — 1,596,423 shares (Direct, null); Voting Common Stock — 101,190 shares (Indirect, See footnote)
Footnotes (1)
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
Shares sold 49,744 shares Total Voting Common Stock sold May 4–6, 2026
Direct holdings after sales 1,580,820 shares Voting Common Stock directly owned after latest transaction
Indirect holdings 101,190 shares Held via C&M Kroeger Nominee Trust with voting and dispositive power
Sale on May 6, 2026 15,603 shares at $29.13/share Open‑market sale of Voting Common Stock
Sale on May 6, 2026 8,098 shares at $28.04/share Open‑market sale of Voting Common Stock
Sale on May 5, 2026 9,544 shares at $28.12/share Open‑market sale of Voting Common Stock
Sale on May 4, 2026 9,136 shares at $27.50/share Open‑market sale of Voting Common Stock
Sale on May 4, 2026 697 shares at $30.08/share Open‑market sale of Voting Common Stock
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
voting and dispositive power financial
"the Reporting Person is co-trustee with his spouse and has voting and dispositive power."
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Voting Common Stock financial
"security_title: "Voting Common Stock""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kroeger Christopher A.
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock05/04/2026S(1)9,136D$27.5(2)1,621,428D
Voting Common Stock05/04/2026S(1)5,427D$28.37(3)1,616,001D
Voting Common Stock05/04/2026S(1)311D$29.56(4)1,615,690D
Voting Common Stock05/04/2026S(1)697D$30.08(5)1,614,993D
Voting Common Stock05/05/2026S(1)9,544D$28.12(6)1,605,449D
Voting Common Stock05/05/2026S(1)928D$29(7)1,604,521D
Voting Common Stock05/06/2026S(1)8,098D$28.04(8)1,596,423D
Voting Common Stock05/06/2026S(1)15,603D$29.13(9)1,580,820D
Voting Common Stock101,190ISee footnote(10)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
/s/ Kristopher L. Hanson, Attorney-in-Fact05/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report on this Form 4?

MapLight Therapeutics reported that CEO and director Christopher A. Kroeger sold Voting Common Stock in several open‑market transactions. Across May 4–6, 2026, he disposed of 49,744 shares, while retaining a substantial direct and indirect ownership position in the company.

How many MapLight Therapeutics (MPLT) shares did the CEO sell and on what dates?

Christopher A. Kroeger sold 49,744 shares of MapLight Therapeutics Voting Common Stock. The sales occurred over three days, May 4, May 5, and May 6, 2026, in multiple open‑market transactions, each reported with a weighted average sale price per share.

At what prices were the MapLight Therapeutics (MPLT) shares sold by the CEO?

The CEO’s shares were sold at weighted average prices reported for each transaction, including prices such as $27.50, $28.04, $28.37, $29.00, $29.13, and $30.08 per share. Each sale reflects multiple trades within a disclosed price range on the relevant date.

How many MapLight Therapeutics (MPLT) shares does the CEO still own after these sales?

Following the reported transactions, Christopher A. Kroeger directly owns 1,580,820 shares of MapLight Therapeutics Voting Common Stock. In addition, 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse have voting and dispositive power.

Were the MapLight Therapeutics (MPLT) insider sales made under a Rule 10b5-1 trading plan?

Yes. A footnote explains these transactions were made pursuant to a Rule 10b5‑1 trading plan adopted by Christopher A. Kroeger on December 29, 2025. Such plans pre‑schedule trades, indicating the timing of these sales was arranged in advance rather than decided opportunistically.

What does the Form 4 reveal about the CEO’s indirect holdings in MapLight Therapeutics (MPLT)?

The Form 4 reports 101,190 shares of Voting Common Stock held indirectly through the C&M Kroeger Nominee Trust. Christopher A. Kroeger and his spouse serve as co‑trustees of this trust and have both voting power and dispositive power over those indirectly held shares.